A Patient with Genetically Confirmed Myoclonus-Dystonia Responded to Anticholinergic Treatment and Improved Spontaneously

The various medical treatments applied to myoclonus-dystonia patients with a mutation of the ε-sarcoglycan gene (SGCE) have not been beneficial in most cases. Most patients experience progressive deterioration or static clinical courses, with only rare cases of spontaneous remission. A 19-year-old g...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical neurology (Seoul, Korea) Vol. 7; no. 4; pp. 231 - 232
Main Authors Lee, Jae Hyeok, Lyoo, Chul Hyoung, Lee, Myung Sik
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Neurological Association 01.12.2011
대한신경과학회
Subjects
Case Report
신경과학
myoclonus
spontaneous remission
anticholinergics
dystonia
Online AccessGet full text
ISSN1738-6586
2005-5013
2005-5013
DOI10.3988/jcn.2011.7.4.231

Cover

More Information
Summary:The various medical treatments applied to myoclonus-dystonia patients with a mutation of the ε-sarcoglycan gene (SGCE) have not been beneficial in most cases. Most patients experience progressive deterioration or static clinical courses, with only rare cases of spontaneous remission. A 19-year-old girl presented with a 14-year history of myoclonus and dystonia that severely affected her left arm, neck, and trunk. Genetic studies showed a mutation in SGCE [deletion in exon 6 (c.771_772delAT, Cys258X)]. Both myoclonus and dystonia responded to anticholinergic treatment for 7 years and improved spontaneously. The possibility of spontaneous improvement should be kept in mind when considering the therapeutic strategy in myoclonus-dystonia patients, especially when contemplating deep-brain stimulation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-002236.2011.7.4.003
ISSN:1738-6586
2005-5013
2005-5013
DOI:10.3988/jcn.2011.7.4.231